Scientific Team

We've constructed a team of specialists dedicated to architecting a revolutionary change in how we treat cancer.

Meet our scientific team

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum.
Timothy P. Cripe, M.D., Ph.D

Dr. Cripe has studied viruses and cancer for over 30 years, beginning with his Ph.D. work on papillomaviruses and their association with cervical cancer with Lubomir Turek at the University of Iowa, where he earned his M.D./Ph.D. In his postdoctoral fellowship at Children’s Hospitals in Boston and Denver, he trained in pediatric hematology/oncology and studied the role of protein chaperones in the assembly of papovaviruses with Robert Garcea in an effort to create genome-deficient gene therapy vectors. He has served on the faculty at the University of Wisconsin-Madison, Cincinnati Children’s Hospital Medical Center/University of Cincinnati, and Nationwide Children’s Hospital/Ohio State University. He has dedicated his research to leveraging virology and molecular biology to develop novel therapeutic approaches to cancer. He is widely recognized as an expert in gene therapy, immunotherapy, and oncolytic viruses. He maintains a clinical practice as the Chief of Pediatric Hematology/Oncology/Blood and Marrow Transplantation at Nationwide Children’s Hospital. He has extensive experience as sponsor-investigator or principal investigator of early phase cancer clinical trials and served as Chair of the FDA Advisory Committee on Cellular, Tissue, and Gene Therapy.

Pin-Yi Wang, Ph.D
Co-Founding scientist

Dr. Wang earned her bachelor’s degree in Medical Technology and her master’s in Microbiology and Immunology from the University of Taipei. She completed her Ph.D. in Pathology and Laboratory Medicine at the University of Rochester School of Medicine and Dentistry. Since 2008 she has studied oncolytic viruses and is an expert in vectorology.

Chun-yu Chen, Ph.D.
Co-Founding scientist

Dr. Chen earned his bachelor’s degree in Medical Technology and his master’s in Microbiology and Immunology from the University of Taipei. He completed his Ph.D. in Chemical Engineering at the University of Rochester in New York and a post-doc in Allergy and Immunology at Cincinnati Children’s Hospital Medical Center in Dr. Yui-Hsi Wang’s laboratory. There he identified novel IL-9 producing mucosal mast cells (MMC9s) that are able to cooperate with CD4+ Th2 cells to influence the severity and susceptibility to ovalbumin (OVA)-induced food allergy. Since 2013 he has studied the immunologic reactions to oncolytic viruses in various cancer models.

Brian Hutzen, Ph.D.
Co-Founding Scientist

Dr. Hutzen earned his bachelor’s degree in Biology at Washington & Jefferson College and completed his Ph.D. in Molecular, Cellular and Developmental Biology at The Ohio State University, where he helped develop oncolytic measles viruses for the treatment of pediatric brain tumors. He joined Dr. Cripe’s lab as a post-doctoral fellow and later a research scientist, where he examines modulation of the tumor microenvironment to improve oncolytic virotherapy.

Mark Currier, M.S.
Co-Founding Scientist

Mr. Currier earned his bachelor’s degree from the University of Mississippi and completed his Master’s degree in Microbiology at Miami University where he studied the molecular mechanisms involved in the enhanced replication of SV40 evolutionary variants. He has served as the lab and program manager in the Cripe Lab since 2000. He has extensive experience in pre-clinical studies using syngeneic and xenograft mouse tumor models to investigate the anti-tumor potential of small molecule inhibitors and viruses. He has served on phase I/II clinical trial teams as the biosafety officer evaluating the safety of HSV-1 in pediatric patients and as a scientist involved in the production tumor vaccines to treat adult solid tumors.

Join the list to receive the latest
news & updates.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form